Ignite Creation Date:
2024-05-05 @ 9:57 PM
Last Modification Date:
2024-10-26 @ 10:11 AM
Study NCT ID:
NCT00991146
Status:
COMPLETED
Last Update Posted:
2020-09-25
First Post:
2009-10-06
Brief Title:
Efficacy and Safety Study of Canakinumab Administered for 6 Months 24 Weeks in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Neonatal Onset Multisystem Inflammatory Disease |
| Cryopyrin-associated Periodic Syndromes |
| Familial Cold Autoinflammatory Syndrome |
| Muckle-Wells Syndrome |
Keywords:
| Name | View |
|---|---|
| familial autoinflammatory syndrome | View |
| CAPS | View |
| FCAS | View |
| MWS | View |
| NOMID | View |
| cryopyrin-associated periodic syndromes | View |
| Familial Cold Autoinflammatory Syndrome | View |
| Muckle-Wells Syndrome | View |
| Neonatal Onset Multisystem Inflammatory Disease | View |
| canakinumab | View |
| ACZ885 | View |
| children | View |
| systemic autoinflammatory disease | View |
| NALP-3 | View |
| human monoclonal anti-human interleukin-1beta IL-1betaantibody | View |
| autosomal dominant | View |